Navigation Links
Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
Date:5/9/2011

"The data from this study demonstrate that patients treated with fidaxomicin were significantly less likely to suffer a relapse of the initial infection within the first two weeks after completing therapy. The data also suggest that late recurrence is likely due to a reinfection from the environment, particularly in patients with risk factors such as elevated white blood cells and low albumin levels at the end of therapy and exposure to concomitant antibiotics."

The second poster presented today demonstrates that DIFICID is minimally absorbed with plasma levels in the low ng/mL range while maintaining high fecal concentration that are well in excess of the MIC90 versus C. difficile. The analysis measured the concentration of DIFICID and its metabolite, OP-1118, in the plasma and feces of patients treated with the drug in the Phase 3 clinical studies. Plasma concentrations were in the low nanogram per milliliter (ng/mL) range for both DIFICID and its metabolite at day 1 and at End-of-Therapy.  By contrast with the plasma concentrations, fecal concentrations were more than 10,000 times higher as fecal levels exceeded 1,000 micrograms/gram (ug/g) for DIFICID and 800 ug/g for its metabolite.  The DIFICID fecal levels were more than 1,000 times the minimum inhibitory concentration for C. difficile of 0.25 ug/mL and consistent with a high level of activity toward the target organism at the intended site of action in the colon.  The poster presentation is titled "High Fecal and Low Plasma Levels of Fidaxomicin and Metabolite OP-1118 in Patients with C. difficile infection:  Combined Results of Two Phase 3 Trials."

"Following oral administration, DIFICID has minimal systemic exposure, even in patients with CDI," said Pam Sears, Ph.D., Executive Director of Biology and Pre-Clinical Science at Optimer.  "These data show that DIFICID tends to stay in the site of infection for this disease."

About DIFICID™
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rhythmia Medical Highlights Studies to be Presented at Heart Rhythm Society 2011 Annual Scientific Session
2. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
3. New Study Results Presented on Dexlansoprazole and Lansoprazole Effects on Plavix® (clopidogrel bisulfate)
4. Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
5. REMEDIAL II Results on PLC Systems RenalGuard® to be Presented at ACC 2011s Late Breaking Clinical Trial Session
6. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
7. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
8. Advancements in GYN Oncology; Instrumentation and Techniques to be Presented by Nicholas C. Lambrou, M.D. of Miami
9. Urocidin™ Phase III Clinical Trial Results to be Presented at EAU and AUA Conferences
10. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
11. New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... of the ResMed Data Exchange program, a comprehensive ... medical equipment (HME) and other health care providers. ... secure access to critical patient information. It integrates ... AirView™ and U-Sleep™ patient management platforms with customers, ...
(Date:10/20/2014)... PRINCETON, N.J. , Oct. 20, 2014 /PRNewswire/ ... Taiho Pharmaceutical Co., Ltd. ( Japan ... Administration (FDA) granted Fast Track designation for TAS-102 ... combination anticancer drug under investigation for the treatment ... the Company has initiated a rolling NDA submission ...
(Date:10/20/2014)... October 20, 2014 Norgine B.V. ... novel, low volume bowel preparation, NER1006, presented at the ... College of Gastroenterology (ACG), Philadelphia, PA ... stool weight and co-primary endpoint of cleansing success. The ... vs. MOVIPREP ® in screening colonoscopy patients. [1] ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) will ... Tuesday, February 15, 2011.  The presentation is scheduled for ... through the Company,s web site, www.regeneron.com , on ... presentation will be available after the live webcast through ...
... Feb. 8, 2011 IPC The Hospitalist Company, Inc. (Nasdaq: ... practice company, announced today that it will report results for ... Monday, March 7, 2011, after the market close. ... 5:00 p.m. ET (2:00 p.m. PT) on March 7, 2011 ...
Cached Medicine Technology:IPC The Hospitalist Company, Inc. to Report Fourth Quarter 2010 Results 2
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, ... of Columbus, Inc., A Division of MaternOhio Clinical Associates, ... than 100,000 patients annually. Dr. Murphy will provide a ... of a women’s life. She is accepting new patients ... and Dublin. , Dr. Murphy offers a wide variety ...
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... , CHADDS FORD, Pa., Aug. 31 Endo Pharmaceuticals (Nasdaq: ... Partners Healthcare Conference 2009 on Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. ... and development programs. , , The presentation will be webcast ... under the investors section. , , ...
... , , VENTURA, Calif., Aug. 31 ... than to receive." However, when the gift one is giving is ... with more than 97 percent organic aloe vera, receiving and giving ... Founded by Rinaldo and Lalla Brutoco, owners of the manufacturer ...
... is over-treatment for many men, researchers say , MONDAY, Aug. ... a test for prostate-specific antigen (PSA) has led to mass ... PSA screening test came into use in 1986, federal government ... the United States has risen substantially, said the report in ...
... 31 (HealthDay News) -- Walk-in retail clinics staffed by nurse ... has found. , Writing in the Sept. 1 issue of ... Ateev Mehrotra said that retail clinics -- which are typically ... other retail chain stores such as Target and Wal-Mart -- ...
... , , ABBOTT PARK, Ill., Aug. ... the Morgan Stanley Global Healthcare Unplugged Conference on Monday, Sept. 14, ... financial officer, will make a presentation on the company at 8:10 ... webcast of the presentation will be accessible through Abbott,s Investor Relations ...
... as fires threaten , , WASHINGTON, Aug. 31 ... evacuees a safe place to stay as wildfires in California force people ... took refuge from the smoke and fire in Red Cross shelters. ... , "If you are ordered to leave your home, please ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:It's Better to Give Than to Receive 2Health News:It's Better to Give Than to Receive 3Health News:Prostate Cancer Over-Diagnosed: Study 2Health News:Prostate Cancer Over-Diagnosed: Study 3Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Red Cross Shelters Wildfire Evacuees 2Health News:Red Cross Shelters Wildfire Evacuees 3
... (CMI) is a type I collagen implant ... tear or loss of meniscus tissue, typically ... The purpose of the CMI is to ... to a more vigorous lifestyle, while forestalling ...
... System is a technological breakthrough in carpal ... minimally-invasive approach, provides significant patient benefits. ... the wrist,creates an entry for the disposable ... standard video camera system, provides a clear ...
... tip, the Finntip Wide is designed especially ... like genomic DNA. This tip eliminates the ... is excellent for use with extremely viscous ... diameter of the orifice is 1.1 mm ...
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
Medicine Products: